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Vaccine development requires accurate scale down models that can provide both qualitative and quantitative
data that can be utilized for process development. With such data, time to pilot scale can be minimized and
provide cost and time savings.
The ambr®250 high-throughput (HT) system is a multi-parallel, single-use mini bioreactor system with
automated liquid handling and automated controls. Implementation of the ambr®250 HT system was evaluated
as a potential scale-down model for several microcarrier production system vaccine candidates and one
microbial production system vaccine candidate.
Many live virus vaccines utilize anchorage-dependent cell lines grown on microcarrier beads. This presents
unique challenges to cultivation in scale down systems and has the potential to complicate scaling models and
generate data that is not representative of the pilot or commercial scale. Initially, the ambr250®HT system did
not generate representative data due to the suspension requirements of the microcarriers and distribution
through the reactors. These challenges were largely addressed through vessel modifications, improvement in
motor speed control, and careful liquid handling practices. The microbial vaccine candidate demonstrated good
comparability to standard lab scale systems following evaluation of several scale-up methods and sampling
method improvement.
The ambr®250 HT system has become a valuable vaccines process development tool, although more work
must be done to fully understand some process performance differences across scales.
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